Translational medicine and drug discovery / edited by Bruce H. Littman, Rajesh Krishna.

04175nam a22003978i 4500

vtls001585299

VRT

20200921122600.0

m|||||o||d||||||||

cr||||||||||||

200921s2011||||enk     o     ||1 0|eng|d

$a 9780511976087 (ebook)

$z 9780521886451 (hardback)

$z 9781107435940 (paperback)

$a (UkCbUP)CR9780511976087

$y 202009211226 $z santha

$a UkCbUP $b eng $e rda $c UkCbUP

$a RM301.25 $b .T73 2011

$a 615/.19 $2 22

$a Translational medicine and drug discovery / $c edited by Bruce H. Littman, Rajesh Krishna.

$a Translational Medicine & Drug Discovery

$a Cambridge : $b Cambridge University Press, $c 2011.

$a 1 online resource (xx, 361 pages) : $b digital, PDF file(s).

$a text $b txt $2 rdacontent

$a computer $b c $2 rdamedia

$a online resource $b cr $2 rdacarrier

$a Title from publisher's bibliographic system (viewed on 05 Oct 2015).

$g Section I. Translational medicine: history, principles and application in drug development: 1. $t Translational medicine:definition, history, and strategies/ Bruce H. Littman -- 2. $t Translational medicine and its impact on diabetes drug development / Roberto A. Calle and Ann E. Taylor -- 3. $t Challenges in atherosclerosis / John S. Millar -- 4. $t Obesity: new mechanisms and translational paradigms / Gregory Gaich and David E. Moller -- 5. $t Bone disorders: translational medicine case studies / S. Aubrey Stoch -- 6. $t Case studies in neuroscience: unique challenges and examples / Gerard J. Marek -- 7. $t Translational medicine in oncology / Dominic G. Spinella; Section II. Biomarkers and public-private partnerships: 8. $t Biomarker validation and application in early drug development: idea to proof of concept/ Pfizer Global Research and Development, 2004 -- 9. $t Image biomarkers in drug development: case studies / Johannes T. Tauscher and Adam J. Schwarz -- 10. $t European new safe and innovative medicine initiatives: history and progress (through December 2009) / Ole J. Bjerrum and Hans H. Linden -- 11. $t Critical path institute and the predictive safety testing consortium / Elizabeth Gribble Walker -- 12. $t The biomarker consortium: facilitating the development and qualification of novel biomarkers through a precompetitive public-private partnership / David Wholley and David B. Lee; Section III. Future Directions: 13. $t Improving the quality and productivity of pharmacometric modeling and simulation activities: the foundation for model-based drug development / Thaddeus H. Grasela, Jill Fiedler-Kelly, and Robert Slusser -- 14. $t Embracing change: a pharmaceutical industry guide to the 21st century / Mervyn Turner.

$a This book, edited by two innovative leaders in the field, focuses on the new discipline of translational medicine as it pertains to drug development within the pharmaceutical and biotechnology industry. Translational medicine seeks to translate biological and molecular knowledge of disease and how drugs work into innovative development strategies that reduce the cost and increase the speed of delivering new medicines for patients. This book outlines general strategies, biomarker development, imaging tools, translational human models and examples of their application to real drug development. The latest thinking is presented by researchers from many of the world's leading drug development companies, including Pfizer, Merck, Eli Lilly, Abbott and Novartis, as well as academic institutions and public-private partnerships that support translational research. This book is essential for anyone interested in translational medicine from a variety of backgrounds: university institutes, medical schools, pharmaceutical companies and drug development researchers and decision-makers.

$a Drug development.

$a MOLECULAR PHARMACOLOGY.

$a Littman, Bruce H., $d 1944- $e editor.

$a Krishna, Rajesh, $e editor.

$i Print version: $z 9780521886451

$u https://doi.org/10.1017/CBO9780511976087

$a VIRTUA